Learn more about whether Glaukos Corporation or iRhythm Technologies, Inc. is a better investment based on AAII's A+ Investor ...

iRhythm Technologies reported strong Q4 2024 results, driven by expanding Zio adoption and operational improvements. The company remains focused on FDA remediation and international expansion ...

iRhythm disclaims any intention or obligation ... thinner and more breathable compared to our legacy Zio XT product. And we unveiled data demonstrating its superior real-world performance at ...

iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, November 19, at 9:50 am Eastern Time. Interested parties may access a live and archived webcast Zio AT device ...

Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 24% year on year to $164.3 million. The company ...

“Our fourth quarter capped a transformative year for iRhythm (IRTC), marked by 24% revenue ... primary care settings where Zio’s value as a population health management tool has resonated ...

iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, November 19, at 9:50 am Eastern Time. Interested parties may access a live and archived webcast Zio AT device, along ...